Lonza's mammalian expression technologies offer commercially viable systems that cover the diversity of complex proteins and are suitable for large-scale development. The combinatorial screening uses a broad range of genetic elements that mitigate the lack of predictability for both the quantity and quality of your target protein. This, combined with extensive experience in establishing customized product-specific assay methods that aid in cell line decisions, gives you the tools you need to be successful in a biopharmaceutical landscape that presents both new challenges as well as exciting opportunities.

  • Rebecca Michael, PhD. Head of Cell & Molecular Biology, Lonza
  • Nathalie Knabe, Head of Strategic Marketing, Mammalian, Lonza
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center